A Phase II Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of ME1111 for 48 Weeks of Treatment in Patients with Mild to Moderate Onychomycosis

开始日期2018-01-24

申办/合作机构

Meiji Seika Pharma Co., Ltd.

NCT03280927

/ Completed临床4期

A Multicenter, Open-label, Non-controlled, Single-arm Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis

The antifungal efficacy and safety of Jublia® topical solution will be assessed through an administration for 48 weeks to patients diagnosed with a mild or moderate onychomycosis due to dermatophyte.

开始日期2017-11-10

申办/合作机构

Dong-A ST Co., Ltd.

100 项与艾氟康唑相关的临床结果

登录后查看更多信息

100 项与艾氟康唑相关的转化医学

登录后查看更多信息

100 项与艾氟康唑相关的专利（医药）

登录后查看更多信息

268

项与艾氟康唑相关的文献（医药）

2026-07-01·JOURNAL OF DERMATOLOGY

Baseline Nail Thickness and Great Toenail Involvement Are Associated With Poor Response to Topical Antifungal Therapy for Onychomycosis: A Lesion‐Level Generalized Estimating Equations Analysis

Article

作者: Amano, Hiroo ; Watabe, Daisuke ; Tsunemi, Yuichiro ; Yasuhira, Shinji ; Sato, Toshiki ; Inoue, Tsuyoshi

ABSTRACT:

Topical antifungals are widely used for onychomycosis; however, lesion‐level morphological predictors of response have rarely been quantified while accounting for within‐patient correlation. We retrospectively studied patients with onychomycosis treated with topical luliconazole 5% nail solution or efinaconazole 10% solution between 2017 and 2021. Eighty lesions from 66 patients were identified. Treatment response was evaluated using lesion‐level generalized estimating equations (GEE) clustered by patient ID with an exchangeable working correlation structure and robust (sandwich) standard errors. Improvement rate (continuous) was analyzed using a linear GEE, and complete cure (yes/no) using a logistic GEE. Great toenail involvement was consistently associated with poor response, showing a lower improvement rate, β = −0.461 (standard error [SE] = 0.145; p = 0.0015), and markedly lower odds of complete cure, odds ratio (OR) 0.07 (95% confidence interval [CI] 0.01–0.37; p = 0.002). Greater baseline nail thickness was associated with lower odds of complete cure, OR 0.17 (95% CI 0.07–0.42; p < 0.001), although it was not significantly associated with improvement rate, β = −0.089 (SE = 0.058; p = 0.125). Use of luliconazole 5% nail solution (vs. efinaconazole 10% solution) was associated with a lower improvement rate, β = −0.310 (SE = 0.154; p = 0.044) and lower odds of complete cure, OR 0.07 (95% CI 0.01–0.60; p = 0.015); these associations should be interpreted cautiously because treatment allocation was not randomized. Sensitivity analyses using a linear mixed‐effects model showed consistent directions of effect. Great toenail involvement appears to be a robust predictor of poor response to topical therapy, and increased nail thickness may particularly hinder achieving complete cure; these findings warrant cautious interpretation given the retrospective, non‐randomized design.

2026-04-30·Medical Mycology Journal

Clinical Management of Antifungal-Resistant Dermatophytosis in Japan

Review

作者: Kano, Rui ; Noguchi, Hiromitsu

Dermatophytosis remains one of the most common superficial fungal infections worldwide, and antifungal-resistant strains have recently emerged as an increasing clinical concern. In Japan, the prevalence of terbinafine-resistant Trichophyton species is currently estimated to be 2%, with most isolates harboring squalene epoxidase (SQLE) gene mutations such as Leu393Phe and Phe397Leu. This review summarizes recent epidemiological findings and representative clinical cases to illustrate the practical management strategies for antifungal-resistant dermatophytosis in Japan. Three illustrative cases were presented. Case 1 involved Trichophyton interdigitale carrying a Phe397Leu mutation that was unresponsive to terbinafine but was successfully treated with topical efinaconazole and luliconazole. Case 2 described a cluster infection of terbinafine-resistant Trichophyton rubrum (Leu393Phe) in a group home, where oral fosravuconazole achieved complete cure. Case 3 reported five soldiers with terbinafine-resistant dermatophytosis caused by Phe397Leu or Phe415Ile mutations, which were likely associated with prolonged topical SQLE inhibitor use. Resistance is often induced by the long-term or intermittent application of SQLE inhibitors, including over-the-counter topical terbinafine and butenafine. For suspected terbinafine-resistant infections, non-SQLE azoles, such as luliconazole and lanoconazole, are recommended because of their 10- to 100-fold increased activity against Trichophyton species. Oral fosravuconazole and topical agents such as 10% efinaconazole or 5% luliconazole have proven effective for onychomycosis. Ongoing surveillance, appropriate antifungal stewardship, and timely adjustment of treatment regimens are essential to prevent the further spread of antifungal-resistant dermatophytosis.

2026-01-01·Journal of Drugs in Dermatology

Topical Efinaconazole 10% for Onychomycosis: Pooled Phase 3 Analysis in White, Black, and Asian Participants

Article

作者: Gupta, Aditya K. ; Lipner, Shari R. ; Guenin, Eric ; Vlahovic, Tracey C. ; Gold, Linda Stein ; Choi, Su Yong ; Elewski, Boni ; Rosen, Ted

BACKGROUND:

Topical efinaconazole 10% solution has demonstrated efficacy and safety in two phase 3 trials of onychomycosis. As clinical data for onychomycosis treatments are limited in patients with skin of color, this post hoc analysis evaluated efinaconazole in participants categorized by race.

METHODS:

Data were pooled from 2 multicenter, double-blind, phase 3 trials (NCT01007708, NCT01008033). Participants aged 18 to 70 years with mild-to-moderate distal lateral subungual onychomycosis in ≥1 great toenail were randomized (3:1) to once-daily efinaconazole or vehicle for 48 weeks. Efficacy endpoints at week 52 included rates of mycologic cure (MC; negative potassium hydroxide examination + negative fungal culture), complete cure (0% clinical involvement + MC), complete/almost complete cure (≤5% clinical involvement + MC), and clinical efficacy (<10% clinical involvement). Adverse events (AEs) were assessed.

RESULTS:

Participants (n=1655) were categorized by self-reported race: White (n=1251), Asian (n=269), or Black (n=98). At week 52, more efinaconazole- vs vehicle-treated participants achieved complete cure (White, 14.7% vs 2.0%; Asian, 27.5% vs 13.0%; Black, 12.9% vs 7.1%), complete/almost complete cure (22.8% vs 4.6%; 35.5% vs 18.8%; 25.7% vs 7.1%), and clinical efficacy (31.2% vs 8.6%; 46.0% vs 23.2%; 31.4% vs 21.4%). Mycologic cure rates were also higher with efinaconazole (range: 53.4%–61.4%) vs vehicle (10.7%–30.4%). Most treatment-emergent AEs with efinaconazole were mild/moderate, with low discontinuation rates (<6%).

CONCLUSIONS:

Topical efinaconazole 10% showed favorable efficacy/safety in White, Asian, and Black participants with mild-to-moderate onychomycosis. Results were generally consistent with the overall phase 3 populations and position efinaconazole as an efficacious treatment for patients, regardless of race. .

项与艾氟康唑相关的新闻（医药）

2026-07-29

·康哲药业

康哲药业：Rxilient获得皮肤科改良新药Finjuve和品牌药Ciclopoli东南亚等市场商业化权利

改良新药Finjuve是全球首个且唯一获批用于雄激素性脱发治疗的外用非那雄胺产品，疗效与口服非那雄胺相当，但全身暴露量较口服低100倍，对血清DHT水平影响更小，提供有效且风险更低的脱发治疗选择品牌药Ciclopoli采用专利HPCH水溶性透甲技术，无需锉甲或有机溶剂去除药膜，兼具良好疗效、安全性及使用便利性，为甲真菌病患者提供更优外用治疗方案依托覆盖东南亚市场的成熟注册及商业化能力，Rxilient将加快推动两款产品落地，为东南亚业务增长注入新动力近日，康哲药业旗下东南亚业务公司Rxilient Medical Pte. Ltd.(“Rxilient”)与专注于医学皮肤科的全球生物制药公司Almirall S.A.旗下Polichem S.A.达成合作，获得改良新药外用非那雄胺喷雾剂Finjuve及品牌药含环吡酮药用指甲油Ciclopoli两款皮肤科产品在东南亚等市场的独家商业化权益。根据协议，Rxilient获得在香港特别行政区、澳门特别行政区、台湾地区、东南亚十一国商业化Ciclopoli的独占经销权利；获得在新加坡、马来西亚、菲律宾、泰国及印尼商业化Finjuve的独占商业化权利。此次合作进一步丰富了Rxilient皮肤科产品组合，将提升其在皮肤科领域的专业实力与市场地位。Rxilient将依托在东南亚等新兴市场成熟的法规与注册事务能力、完备的商业化基础设施，以及覆盖区域的广泛医疗专家网络，加速两款新产品的注册与市场导入，充分释放运营协同效应。同时，Finjuve已于2025年在新加坡、马来西亚获批上市，成为当地首个且唯一获批用于雄激素性脱发治疗的外用非那雄胺产品，预计将快速带动东南亚业务的收入增长。 Finjuve：全球首个且唯一获批用于雄激素性脱发治疗的外用非那雄胺产品 Finjuve 是一种处方外用非那雄胺(finasteride)制剂，用于治疗成年男性雄激素性脱发，尤其适用于轻至中度患者。此前，Finjuve已于中国、欧盟多国、中东及拉丁美洲获批上市，是全球首个且唯一获批用于雄激素性脱发治疗的外用非那雄胺产品。Finjuve 以每日一次的皮肤喷雾方式给药，通过抑制头皮中的 II 型 5α-还原酶，从而降低局部二氢睾酮(DHT)水平——DHT 是导致毛囊微小化的关键驱动因素——进而促进毛发生长并防止进一步脱发。其主要应用场景是作为口服非那雄胺的替代方案，尤其适用于担心全身性副作用的患者。 Finjuve的国际III期临床研究显示，治疗24周后，患者头皮毛发计数较基线增加约20根/cm²，疗效与口服非那雄胺相当[1]；同时，全身暴露量较口服低100倍，对血清DHT水平影响更小，全身不良反应发生率与安慰剂无显著差异，局部耐受性良好[2]。 Finjuve 所处的是全球快速增长的脱发治疗市场——该市场由高患病率（男性一生中受影响比例可达约80%[3]）、消费者认知提升，以及对非侵入性、皮肤科主导解决方案的强劲需求所驱动；其中，外用及皮肤科处方治疗相较于米诺地尔等传统非处方(OTC)产品属于疗效更优、更高端化的细分领域。Finjuve定位为下一代、差异化的外用抗雄激素治疗，兼顾疗效与安全性，面向规模庞大且持续扩张的患者群体，为其提供有效且风险更低的脱发治疗选择。 Ciclopoli：为甲真菌病患者提供更优外用治疗方案 Ciclopoli 是一种含有环吡酮胺(ciclopirox)的外用抗真菌指甲油（指甲油剂型），主要用于治疗轻至中度甲真菌病（灰指甲），尤其适用于未累及甲母质的病例。它是轻至中度疾病的一线治疗选择[4]，也适用于因安全性顾虑而希望避免或不优先选择口服抗真菌药等系统性治疗的患者。 Ciclopoli的核心优势源于其专利HPCH（羟丙基壳聚糖）水溶性透甲技术[5,6]。HPCH是一种生物聚合物成膜剂，能显著提升环吡酮在甲板中的渗透深度与局部药物浓度[6]，且无需有机溶剂或指甲锉去除，仅用水清洗即可，避免对甲板和周围皮肤的二次损伤[5,6]。在轻至中度甲癣的临床研究中，8%环吡酮HPCH指甲油在完全治愈率、治疗成功率和真菌学治愈率方面均显著优于阿莫罗芬5%指甲油[7]。其疗效亦优于市售水不溶性环吡酮8%指甲油[6]。且环吡酮通过独特的螯合机制抑制真菌金属依赖性酶[8,9]，作为外用抗真菌药已有40余年临床使用经验，未见临床耐药报道[9,10]。在全球范围内，Ciclopoli定位于甲真菌病治疗领域中的外用细分市场，同类外用甲涂剂产品包括阿莫罗芬(amorolfine)、依芬康唑(efinaconazole)和他伐硼罗(tavaborole)等。凭借已确立的安全性、较低的成本以及广泛可及性，Ciclopoli 具备较强的竞争优势。总体而言，它是一款基础性、高销量的皮肤科产品，覆盖庞大的患者群体，满足对安全、非系统性治疗方案的需求。甲真菌病在全球的患病率为 5.5%[11]，其中，东南亚地区患病率最高[12]。由于当地气候温暖潮湿、人们常穿密闭鞋履，以及糖尿病和肥胖发生率不断上升，甲真菌病的治疗仍存在巨大的未满足需求[12]。当前在相关市场中可选治疗手段相对有限，为 Ciclopoli 等新进入产品带来良好的市场机遇。关于Rxilient Rxilient是一家深度布局全球新兴市场的新型药企，具备从医药产品开发注册、生产到本土商业化的全链条能力，其运营网络已覆盖东南亚、中东、北非及港澳台地区。关于康哲药业康哲药业是一家专注于差异化专科医药产品的识别、构建与全生命周期管理的创新型医药企业，以自主研发与合作研发双轨并行，依托从零创建市场与品牌的能力，让每一款药品的临床价值和商业价值充分实现。康哲药业已形成贯穿产品全生命周期的能力闭环，精准识别优质创新标的，为其匹配最优研发路径，高效推进临床开发与注册；围绕诊疗需求精准制定医学策略，依托专业学术推广体系及网络，推动产品实现规模化临床应用。康哲药业聚焦心肾代谢、中枢神经、消化、眼科、皮肤健康等优势专科，以专业学术推广与多疾病领域学术资源，构建可持续的专科规模优势，皮肤健康业务已成为细分领域龙头。同时，持续推进国际化复制能力建设，在东南亚及中东等新兴市场验证商业模式的可迁移性，为集团高质量可持续发展注入长期动能。参考文献/资料 1. Piraccini BM, Blume-Peytavi U, Scarci F, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. J Eur Acad Dermatol Venereol. 2022;36(2):286-294. 2. Finjuve Summary of Product Characteristics. Apotex Inc. 3. Piraccini BM, Alessandrini A, Starace M. Androgenetic alopecia. G Ital Dermatol Venereol. 2014;149(1):15-24. 4. 产品相关信息可在Polichem官网查询，网址：https://www.polichem.com/products/ciclopoli-nail-lacquer/ 5. Baran R, Tosti A, Hartmane I, et al. An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis. J Eur Acad Dermatol Venereol. 2009;23(7):773-781. 6. Piraccini BM, Iorizzo M, Lencastre A, et al. Ciclopirox Hydroxypropyl Chitosan (HPCH) Nail Lacquer: A Review of Its Use in Onychomycosis. Dermatol Ther (Heidelb). 2020;10(5):917-929. 7. Iorizzo M, Hartmane I, Derveniece A, et al. Ciclopirox 8% HPCH Nail Lacquer in the Treatment of Mild-to-Moderate Onychomycosis: A Randomized, Double-Blind Amorolfine Controlled Study Using a Blinded Evaluator. Skin Appendage Disord. 2016;1(3):134-140. 8. Sonthalia S, Agrawal M, Sehgal VN. Topical Ciclopirox Olamine 1%: Revisiting a Unique Antifungal. Indian Dermatol Online J. 2019;10(4):481-485. 9. Subissi A, Monti D, Togni G, Mailland F. Ciclopirox: Recent nonclinical and clinical data relevant to its use as a topical antimycotic agent. Drugs. 2010;70(16):2133-2152. 10. WHO Essential Medicines List Expert Committee. Proposal for the Inclusion of Ciclopirox Hydroxypropyl Chitosan in the WHO Model List of Essential Medicines for the Treatment of Onychomycosis in Adult Patients. 11. Onychomycosis: background, pathophysiology, etiology. Medscape. 2024. Available from: https://emedicine.medscape.com/article/1105828-overview 12. Wongyikul P, Lumkul L, Preechasuth K, Phinyo P, Chieosilapatham P. Global and regional prevalence, aetiology and socioeconomic distribution of onychomycosis: a systematic review and meta-analysis (2013–2023). J Epidemiol Community Health. 2026;doi:10.1136/jech-2025-224978. 康哲药业免责与前瞻性声明本新闻无意向您做任何产品的推广，非广告用途。本新闻不对任何药品和医疗器械和/或适应症作推荐。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。由康哲药业编制的此新闻不构成购买或认购任何证券的任何要约或邀请，不形成任何合约或任何其他约束性承诺的依据或加以依赖。本新闻由康哲药业根据其认为可靠之资料及数据编制，但康哲药业并无进行任何说明或保证、明述或暗示，或其他表述，对本新闻内容的真实性、准确性、完整性、公平性及合理性不应加以依赖。本新闻中讨论的若干事宜可能包含涉及本集团的市场机会及业务前景的陈述，该等陈述分别或统称为前瞻性声明。该等前瞻性声明并非对未来表现的保证，存在已知及未知的风险、不明朗性及难以预知的假设。本集团并不采纳本新闻包含的第三方所做的任何前瞻性声明及预测，本集团对该等第三方声明及预测不承担责任。

2026-07-09

·轩硕医药科技

关于肺纤维化相关靶点以及药物介绍

关于肺纤维化相关靶点以及药物介绍特发性肺纤维化（IPF）是一种致命的慢性肺部疾病，目前全球已获批的标准治疗药物是吡非尼酮和尼达尼布，以及2025年新获批的奈拉尼司他（nerandomilast）。不过，这些药物主要作用是延缓疾病进展，无法逆转已形成的肺纤维化，因此针对新靶点的药物研发十分活跃。下面这张表梳理了肺纤维化的核心病理机制和关键靶点，以及现有及在研的代表药物。已上市药物的现状与局限目前全球仅有少数几款药物获批用于治疗IPF，它们是当前的标准疗法，但存在明显不足。吡非尼酮 (Pirfenidone)：作用机制尚未完全阐明，但已知具有抗纤维化（主要抑制TGF-β）、抗炎和抗氧化特性。临床试验证实其能减缓患者用力肺活量（FVC）的下降速度。常见副作用包括恶心、皮疹和光敏反应。尼达尼布 (Nintedanib)：一种多靶点酪氨酸激酶抑制剂，通过阻断血小板源性生长因子受体（PDGFR）、成纤维细胞生长因子受体（FGFR）和血管内皮生长因子受体（VEGFR），直接抑制成纤维细胞的活化与增殖。同样被证实能延缓FVC下降。主要副作用是腹泻，部分患者可能因无法耐受而停药。奈拉尼司他 (Nerandomilast / BI 1015550)：作为十年来首个全新机制的获批药物，它是一种选择性PDE4B抑制剂，通过升高细胞内cAMP水平发挥抗炎和抗纤维化作用。III期临床试验显示，在52周内，18mg剂量组患者的FVC下降幅度显著小于安慰剂组（-114.7 mL vs -183.5 mL）。处于后期临床阶段的在研新药这些药物有望在未来提供新的治疗选择，其中一些已进入III期临床试验。 BMS-986278：一种LPA1受体拮抗剂，通过阻断溶血磷脂酸（LPA）介导的促纤维化信号发挥作用，已进入III期临床。 TDI01：全球首个进入III期临床的高选择性ROCK2抑制剂，通过多维度调节血管渗漏、纤维化和炎症来干预疾病。伊非尼酮 (Efinaconazole / HEC-585)：中国自主研发的IPF新药，是一种多靶点抗纤维化药物，能同时抑制TNF-α和TGF-β1等核心通路，已启动III期临床。新兴作用机制与临床潜力除了上述主流靶点，一些全新机制的研究也展现了转化潜力，标志着治疗思路正从“延缓”向“逆转”迈进。 IL-11抑制剂 (BI 765423)：IL-11是驱动多器官纤维化的关键细胞因子。临床前研究表明，抗IL-11治疗不仅能阻止纤维化，还有望恢复屏障功能、改善肺功能。勃林格殷格翰的BI 765423已在II期研究中评估其对IPF患者的疗效。 TNIK抑制剂 (INS018_055/Rentosertib)：这是全球首个由AI全程驱动研发的药物。其靶点TNIK的异常激活会加速纤维化。在中国进行的IIa期试验中，最高剂量组患者的FVC平均提升了98.4毫升（安慰剂组下降20.3毫升），初步展现了逆转肺功能下降的潜力。 PDPN抗体 (SZ168)：Podoplanin（PDPN）在IPF患者中高表达，与成纤维细胞分化相关。靶向PDPN的单抗SZ168在动物模型中显示出抗纤维化效果，为临床治疗提供了新思路。总结肺纤维化的治疗正进入一个靶向化和多样化的新时代。虽然现有标准疗法对延缓疾病进展至关重要，但新一代药物通过靶向TGF-β活化、LPA1、PDE4B、ROCK2乃至IL-11等更上游或核心的靶点，不仅旨在更好地延缓疾病，更展现出逆转纤维化的潜力。关于我们轩硕医药（轩德医药），是一家专注于生物医药上游领域的专业CDMO企业。公司核心业务聚焦小分子、核酸类、多肽类及XDC药物注册起始物料的工艺开发与规模化生产，始终以成为全球医药行业CDMO服务的高质量交付者为核心战略定位，深耕医药定制研发生产赛道。公司研发中心坐落济南，研发总面积超一万平方米，搭建了覆盖小分子、核酸类、多肽类及XDC药物的专业化工艺研发团队。依托成熟的研发体系与丰富的项目经验，可提供药物从早期工艺开发到原料药高级中间体生产的全链条服务。同时，公司持续深耕连续流化学、酶催化等前沿制药技术，积极布局绿色化、安全化、智能化的先进制药制造模式，持续赋能生物医药产业技术创新与升级发展。公司标准化生产基地位于山东宁阳省级化工产业园，配备四座专业化生产车间，年度制造产能可达500吨。自成立以来，公司始终将质量管控作为企业发展的核心战略，建立了完善、严苛的全流程质量管理体系，目前已累计通过全球各大制药企业审计500余次，质量合规能力获得海内外市场的充分认可。凭借专业的研发实力、完善的硬件配套以及成熟的质量管控体系，轩德医药能够为客户提供高性价比、高品质、高效率的一体化交付服务，积累了稳定优质的全球客户资源，树立了良好的行业口碑。立足未来，轩德医药将持续提升质量管理体系、增强生产交付能力、深耕细分医药领域，精益求精打磨每一款产品。我们诚挚欢迎海内外各界合作伙伴莅临考察、洽谈合作，携手深耕生物医药产业，共创共赢发展新格局！扫码关注了解更多相关资讯

2026-03-19

·Business Wire

New Drug Cost Study: Canadian Online Pharmacies Offer Up to 89% Savings Versus GoodRx and Amazon for U.S. Consumers, Says Campaign for Personal Prescription Importation

HILLSBOROUGH, N.J.--(BUSINESS WIRE)--The Campaign for Personal Prescription Importation (CPPI), a non-profit advocate for affordable access to prescription medications, has released a new price comparison study highlighting the stark differences between U.S. and Canadian pharmacy prices for popular brand-name prescription drugs. We’re in an affordability epidemic. With the ability to personally import essentially identical medications from Canada, U.S. consumers can find desperately needed relief. Using data researched in Mar. 2026, CPPI’s analysis shows that for a sample of 10 popular, name-brand prescription medicines – all daily maintenance medications for common conditions – U.S. consumers can save 52% to 89% by purchasing from licensed Canadian online pharmacies. These results show personal importation from Canada continues to be a significant option for those facing exorbitantly high drug costs. America in a Drug “Affordability Epidemic” CPPI’s study underscores how U.S. prescription costs outpace affordability – as a great number of Americans are dangerously non-compliant with their drug therapy. For instance, a recent survey from the Kaiser Family Foundation (KFF) reveals that about one in five adults (21%) have not filled a prescription due to cost. Additionally, the KFF survey finds about one in seven adults say they have cut pills in half or skipped doses of medicine in the last year because of the cost. “These results highlight the ongoing need for easily accessible alternatives to notoriously high U.S. pharmaceutical prices. We’re in an affordability epidemic,” said CPPI’s Executive Director Ken Hunter. “Millions of Americans are on fixed incomes, have high-deductible health plans that skyrocketed in price when Affordable Care Act subsidies ended in December, or can’t afford insurance at all. With the ability to personally import essentially identical medications from Canada, consumers can find desperately needed relief.” CPPI’s findings, drawn from research comparing GoodRx and Amazon prices in the U.S. against Canadian equivalents, demonstrate average savings of over 64% across 10 commonly prescribed brand-name drugs. These include treatments for conditions including Type 2 diabetes, blood clots, and overactive bladder. Top savings examples for 90-day supplies include: Jublia (12 ml, antifungal): U.S. GoodRx price $2,236.00, U.S. Amazon price $2,502.10, Canadian pharmacy average $257.77 – 89% savings. Xifaxan (550 mg, treats IBS): U.S. GoodRx price $10,036.00, U.S. Amazon price $11,233.90, Canadian pharmacy average $2,325.78 – 78% savings. Myrbetriq (50 mg, treats overactive bladder): U.S. GoodRx price $1,129.00, U.S. Amazon price $994.78, Canadian pharmacy average $314.57 – 70% savings. Additional drugs researched in the study included Xarelto, Jardiance, Rybelsus, Farxiga, Trintellix, Premarin, and Eliquis. The full comparison chart of the 10 popular prescription medications is at https://shorturl.at/odDrW. "With U.S. drug prices being less affordable for millions, this study shows personal prescription importation from licensed Canadian pharmacies remains a proven lifeline that is available today," said Hunter. "Our data shows consumers can slash costs on essential brand-name medications, allowing them to prioritize health without financial ruin. This transforms lives, and Americans should know they have this safe, reliable option." For more information on safe importation and to join (for free) the fight for affordable medications, visit www.PersonalImportation.org. Methodology: Prices obtained Mar. 2026 for 90-day supplies. Amazon pricing is for delivery to N.J.; GoodRx pricing is from N.J. pharmacies using cash price with the lowest after-coupon discount price; Canadian mail-order pricing uses the average of a cross-section of pharmacies certified by Canadian International Pharmacy Assn. (CIPA.com) and is for Health Canada-approved, brand-name products dispensed by a pharmacy licensed in Canada. Savings based on average of GoodRx and Amazon prices. At time of survey, Rybelsus 7 mg was priced but unavailable at Amazon. All registered trademarks referred to herein belong to their respective owners. About CPPI: The Campaign for Personal Prescription Importation (CPPI), based in Hillsborough, N.J., is a national nonprofit patient advocacy organization fighting for Americans' access to safe, affordable prescription medications from Canada for personal use. Tens of millions of Americans – especially the elderly and others on fixed incomes – struggle to pay the extremely high prices of prescription medications in the U.S. CPPI is their voice. For more information and to join us: www.PersonalImportation.org.

100 项与艾氟康唑相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10021	艾氟康唑	D01AC19	DB09040

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
真菌病	德国	Almirall SA	2024-10-02
真菌病	意大利	Almirall SA	2024-10-02
甲癣	美国	Bausch Health Americas, Inc.	2014-06-06

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02812771 (CTgov)	临床4期	甲癣	62	Efinaconazole	構夢獵觸顧蓋觸遞鬱齋 = 糧衊鏇鹹鹽蓋廠願選鹽鬱鏇齋憲積膚壓淵構蓋 (獵鬱鑰遞觸範鹹鹹鹽築, 醖鑰蓋壓鬱獵繭繭簾觸 ~ 醖衊鑰遞醖繭鹹醖鏇醖) 更多	-	2021-11-01
NCT03168841 (CTgov)	临床3期	糖尿病 \| 甲癣	40	Efinaconazole Topical	窪繭餘範鏇範襯壓構壓 = 艱遞廠積鑰膚憲廠鏇遞蓋範廠積構範齋積觸築 (衊齋醖淵鹽觸鏇製鬱壓, 餘鏇廠鬱糧壓壓壓築壓 ~ 餘構壓鹽鑰憲範衊顧範) 更多	-	2019-10-23
NCT03110029 (CTgov)	临床4期	甲癣	13	Efinaconazole 10% Topical Application Solution [JUBLIA]	餘廠構網製糧壓範淵鑰(鬱選廠製襯膚積壓鹹繭) = 蓋壓鏇鏇鏇鑰餘蓋繭網餘襯鹽觸築製觸構糧壓 (構遞憲窪糧糧鑰範網鏇, 繭鏇構艱鏇淵襯夢襯衊 ~ 艱膚膚選憲鹹壓鹽觸餘) 更多	-	2019-03-20
NCT01008033 \| NCT01007708 (Pubmed)	临床3期	甲癣	-	Efinaconazole 10% solution	鹽願壓壓鑰網鹽艱鬱憲(遞膚積願糧願夢醖範夢) = 範製餘選積網鹽簾衊淵遞壓鑰窪醖糧積壓齋衊 (繭壓願築範鏇醖膚膚淵 ) 更多	-	2014-07-01
				Vehicle	鹽願壓壓鑰網鹽艱鬱憲(遞膚積願糧願夢醖範夢) = 觸網製醖鑰獵獵鏇廠廠遞壓鑰窪醖糧積壓齋衊 (繭壓願築範鏇醖膚膚淵 ) 更多
NCT01008033 \| NCT01007708 (Pubmed)	临床3期	甲癣	-	Efinaconazole 10% solution	觸膚鹹遞憲窪鑰鏇鹽廠(觸觸憲鬱襯簾顧糧觸築) = 齋壓網顧構觸願鹽餘壓鹽顧獵遞鹽積窪遞鏇製 (壓顧窪積遞網築鬱衊鹽 ) 更多	-	2014-07-01
				Vehicle	觸膚鹹遞憲窪鑰鏇鹽廠(觸觸憲鬱襯簾顧糧觸築) = 衊鏇選鹹製膚簾選積夢鹽顧獵遞鹽積窪遞鏇製 (壓顧窪積遞網築鬱衊鹽 ) 更多
NCT00777868 (Pubmed)	临床2期	甲癣	135	Efinaconazole 10% solution (with or without semiocclusion)	願顧鏇積蓋醖壓淵膚糧(鏇網糧壓繭夢醖艱遞範) = 憲鏇構範醖範壓餘願觸膚窪鑰繭遞夢簾鏇繭餘 (餘齋遞鑰鏇築餘夢壓憲 ) 更多	-	2013-02-01
				Efinaconazole 5% solution	蓋積顧夢憲築衊鹹夢構(鹽繭蓋構鏇鹹顧廠餘繭) = 築淵願製鏇構製製網鹹鏇鹽觸窪鹽淵夢繭鏇憲 (鏇願窪淵衊製憲願鹽鹹 )
NCT00777868 (Pubmed)	临床2期	甲癣	135	Efinaconazole 10% solution (with or without semiocclusion)	積網艱鹹範壓廠獵齋廠(獵壓襯築遞糧鑰築選窪) = 糧鏇範壓鬱鑰夢艱顧襯範糧觸積製範選醖範鏇 (鑰積鹹憲獵淵製艱鏇蓋 ) 更多	-	2013-02-01
				Efinaconazole 5% solution	壓築廠範顧齋鑰淵夢願(獵衊憲觸築繭窪積壓築) = 壓積餘鏇遞淵廠鹹憲範積獵範夢醖觸鏇簾壓獵 (範膚糧醖艱鑰壓鹹衊窪 )